Table 1.

Summary of evidence.

Intervention Performed	Effects Observed	Source
Angiotensin 2 infusion	Reduced post-stroke mortality Enhanced cerebral perfusion	Fernandez et al. [55]
Ang-(1-7) treatment with ischemic stroke	Decreased microglial activation and neuronal-derived chemokines	Haberl et al. [57]
Ang-(1-7) treatment with ischemic stroke	Reduced nitric oxide secretion Decreased level of CXCL12, IL1-beta, IL6, CD11B	Regenhardt et al. [58]
Ang-(1-7) treatment with ischemic stroke	Reduction of cerebral infarction volume Improvement of neurological function No effect on blood pressure, heart rate, or cerebral blood flow	Bennion et al. [59]
Ang-(1-7) treatment with ischemic stroke	Reduction of cerebral infarction volume Effect was blocked by A779 co-infusion	Meca et al. [34]
Ang-(1-7) treatment with hemoraghic stroke	Increased life expectancy Improved neurological function Decreased microglical activation	Regenhardt et al. [60]
Candesartan treatment before and after MCA occlusion	Increased cerebral blood flow in affected hemisphere Reduction of cerebral infarction volume	Engelhorn et al. [61]
Candesartan post-stroke treatment	No effect on arterial blood pressure Raised expression of mRNA of brain-derived neurotrophic factor	Dai et al. [63]
Candesartan treatment in hypertensive rats with MCA oclusion	Raised expression of mRNA of brain-derived neurotrophic factor	Alhusban et al. [64]
Candesartan chronic treatment	Improved cerebral vascular self-regulation Reduction of cerebral infarction size	Nishimura et al. [62]
C21 treatment before and after MCA oclusion	Reduction of cerebral infarction volume Improved neurological function	Joseph et al. [65]
C21 treatment 5 days after MCA occlusion	Reduction of cerebral infarction volume	McCarthy et al. [66]
C21 treatment after MCA occlusion and reperfusion	Improved survival rate Improved neurological function Decreased neuron apoptosis rate	Schwengel et al. [67]
C21 treatment in MCA occlusion	Reduction of cerebral infarction volume Improved neurological function Reduced production of TNF-alpha and anionic superoxides	Min et al. [68]
C21 treatment after embolic stroke	Improved neurological function Reduction of hemorrhagic transformation	Ishrat et al. [69] Hill et al. [70]
C21 treatment in diabetes mellitus post-stroke model	Reduced mortality rate Improved cognitive function	Jackson et al. [72]
CGP42112 treatment in MCA occlusion	Improved neurological function Reduced lesion progression	McCarthy et al. [73]